ADUS heads into the week after its May 4 earnings print with short sellers pulling back and options traders showing little alarm — yet analyst target cuts keep arriving, keeping the stock well below where most of the Street thinks it belongs.
Short interest has told an interesting story across the past month. Positions peaked above 5.3% of the free float in early April — close to 1 million shares — before sellers retreated sharply around April 9. That move took SI down to roughly 4.97% by April 29. It has since crept back to 5.28%, up about 5% on the week. The borrow market remains relaxed throughout: cost to borrow is only 0.50%, up modestly from 0.46% a week ago, and availability is wide. The ORTEX short score of 41.8 ranks in the 37th percentile of the universe — low enough that short interest is more of a background note than a central concern. This is not a crowded short.
Options sentiment points in the same direction. The put/call ratio has actually eased this week to 0.28, well below its 20-day average of 0.27 and a long way from the 52-week high of 0.55. The z-score is essentially flat at 0.12. After the stock fell 1.1% the day following the May 4 print, options traders are not rushing to hedge further. Last quarter's reaction was also modest: earnings in April produced a 3.3% next-day gain and a 4.6% five-day move. The muted options positioning after this week's softer reaction suggests the market has largely digested the result.
The Street, however, keeps revising estimates lower. Citizens trimmed its target to $142 from $150 on May 6 while holding a Market Outperform rating — a useful signal that even bulls are marking down their expectations. Barclays, the lone underweight on the name, cut its target to $102 in March, now sitting $4 below the current price. The consensus mean target is $134, implying around 36% upside from $98.44 — a wide gap that reflects how far the stock has drifted from where the bullish analysts anchored. The bull case rests on organic revenue growth running at 7-12% and an expected Medicare Hospice rate increase, while the bear case centres on the stock's near-total Medicaid revenue dependence (around 97%) and the legislative risk posed by proposed Medicaid cuts. The ORTEX composite score improved to 76 as of May 6, driven by a sharp move in the value sub-score, which pushed to the 68th percentile — suggesting the market is beginning to price in some of that policy risk.
Insider activity carries no alarm signals. The most recent trades were a cluster of routine sell transactions on February 25 across multiple executives — CFO Brian Poff, the Chief Legal Officer, and several EVPs — all small relative to their total holdings and all at prices above $105. One additional EVP sale in April at $93.61 is the only trade since then. Net 90-day insider activity is positive at roughly 27,000 shares, though that appears to reflect option exercises rather than open-market purchases. The institutional picture is steady: BlackRock holds 15.4% and recently added 67,500 shares, while Westwood Management initiated a new position of 375,000 shares in Q1. Capital Research, trimming from a large base, and a few smaller active managers have reduced exposure.
Peer context adds texture. Close peers OPCH and AHCO have had far rougher weeks — OPCH fell 23% and AHCO dropped 12% over the past seven days, underperforming ADUS's near-flat performance sharply. CHE and UHS both gained around 1.5-1.8%. ADUS's relative stability after its own earnings looks notably resilient by comparison. The next scheduled earnings event is June 10, setting up a roughly five-week window where the Medicaid legislative debate is the dominant variable to monitor.
See the live data behind this article on ORTEX.
Open ADUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
